関連する実験動画
Updated: Jun 20, 2026
09:55
Monitoring Acupuncture Effects on Human Brain by fMRI
Published on: April 8, 2010
15.6K
異なる偽の治療法の非特異的な効果と真治療の有効性への影響:体系的なレビューとネットワークメタ解析のためのプロトコル
Qilin Liu1, Jiahui Yang1,2, Meng Lin1
1Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
BMJ open
|August 21, 2025
まとめ
この体系的なレビューとネットワークメタアナリシスでは 偏頭痛に対する治療の効果を評価し,様々な偽治療の効果を比較した. 真の治療効果を明らかにし,偽の介入の影響を理解することを目的としています.
科学分野:
- 神経学
- 統合医療
- 臨床流行病学
背景:
- 片頭痛は,世界的に大きな影響を与える 広範囲にわたる神経疾患です.
- 治療は 片頭痛に対する一般的な補足療法ですが,その有効性は議論されています.
- 偽の術の技術における変動は,真の治療効果の評価を複雑にする.
研究 の 目的:
- 偏頭痛に対する治療に関するランダム化対照試験 (RCT) を体系的にレビューし,ネットワーク化してメタ分析する.
- 様々な偽薬 (SA) の対照薬と比較して,の有効性を比較する.
- SA方法と影響要因の非特異的な差異的効果を調査する.
主な方法:
- 2024年11月までの複数のデータベースで,偏頭痛における治療とASを比較したRCTを徹底的に検索する.
- 含有基準:SA対照を持つRCT;除外:慢性片頭痛のみ
- 主要アウトカム:偏頭痛の頻度における標準平均差 (SMD);次要アウトカム:応答率,薬物使用,疼痛の強度など
- RoB 2ツールによるバイアスのリスク評価;Stata V.18.0を用いたネットワークメタ解析.
主要な成果:
- 研究プロトコルは,周波数 NMA の方法論を概説しています.
- 分析は,SAに対するの効果の大きさを評価し,異なるSA方法を比較します.
- 異質性,ネットワークの不一致性,出版のバイアスを検討する.
結論:
- このNMAは,異なる偽のコントロールを考慮して,片頭痛に対する治療の包括的な評価を提供します.
- これらの発見は,非特異的な効果を超えて,の特定の治療効果を明らかにするのに役立ちます.
- 結果は 臨床的実践と 未来の研究に役立つでしょう 偏頭痛管理のための 治療について
さらに関連する動画
関連する概念動画
01:54The Placebo Effect
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
02:07Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.